Neurocrine sells Ingrezza for movement disorders.
Neurocrine Biosciences, Inc. (NBIX) is expected to report earnings on Monday, November 2, 2026, after the close. Estimated release time 16:02 ET. Consensus EPS estimate is $1.91.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | Jun 2026 qtr | $1.65 | $1.39 | — | $959.00M |
| 2026-05-05 | Mar 2026 qtr | $1.22 | $1.94 | — | $814.50M |
| 2026-02-11 | Dec 2025 qtr | $1.80 | $1.88 | — | $805.50M |
| 2025-10-28 | Sep 2025 qtr | $1.58 | $2.04 | — | $794.90M |
| 2025-07-30 | Jun 2025 qtr | $0.98 | $1.06 | — | $687.50M |
| 2025-05-05 | Mar 2025 qtr | $0.54 | $0.08 | — | $572.60M |
| 2025-02-06 | Dec 2024 qtr | $1.62 | $1.69 | +4.3% | $627.70M |
| 2024-10-30 | Sep 2024 qtr | $1.51 | $1.24 | — | $622.10M |
NBIX has beaten consensus EPS in 1 of its last 1 scored quarters.
See NBIX on the live calendar →